Clinical Trials Logo

MS clinical trials

View clinical trials related to MS.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05102682 Completed - Multiple Sclerosis Clinical Trials

Robotics for Mobility Rehabilitation in MS

RAPPERIII
Start date: March 10, 2017
Phase: Phase 1
Study type: Interventional

Title Prospective, open label, single arm, non-randomized, non-comparative feasibility study of Rex robot assisted rehabilitation exercise to enhance balance, mobility and upper limb function in people with Multiple Sclerosis "RAPPER III - MS Objective The objective of this study is to evaluate the feasibility and safety of the REX Robot when used for rehabilitation with people who have moderate to severe mobility restrictions due to MS. A secondary objective of the study is to explore the acceptability of the device to people with MS and its impact on impairments and functions commonly affected by MS. Study Sponsor Rex Bionics, Plc. Study Device REX Robotic powered exercise system Primary Endpoint • Completion of a transfer, stand, balance and walk rehabilitation session. - Unexpected Serious Adverse Events Secondary Endpoints - Completion of a transfer, stand, balance and walk rehabilitation program over Six-weeks - The Number of approached, screened, and eligible potential participants. Reasons for Ineligibility. (See 'RAPPER III- MS 007 Screening Loss Analysis REV 0 FINAL') - Functional Ambulation Classification (FAC) 1 - Activities-specific Balance Confidence (ABC) Scale 2 - Modified Falls Efficacy Scale (MFES) 3, 4, - Multiple Sclerosis Walking scale (MSWS-12) 5 - Multiple Sclerosis Impact scale (MSIS-29) 6 - ARMA (arm activity measure) 7 - Berg Balance Scale 8 - Timed unsupported steady stand (TUSS) 9 - Pain scale questionnaire (Visual Analog Score VAS) 10 - Modified Ashworth Score 11 - Spasticity Impact Scale 12 - Epworth Sleepiness Scale (ESS) questionnaire 13 - EQ-5D Health State Questionnaire 14 Questionnaires may be administered in person, by phone, email or in the post.

NCT ID: NCT01128075 Completed - Multiple Sclerosis Clinical Trials

Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects

MEASURE
Start date: August 2009
Phase: N/A
Study type: Observational

This is a multi-center, two-arm non-comparative, observational, 96 week Phase IV study to evaluate treatment adherence when using RebiSmart™ for self-injection of Rebif® in subjects with relapsing multiple sclerosis (RMS). Subjects who have a confirmed diagnosis of RMS using McDonald Criteria and meet the eligibility criteria during a screening period of up to 28 days will be provided with an electronic self-injection device (RebiSmart™) to inject Rebif® for 96 weeks. The main purpose of this study is to evaluate treatment adherence for subjects with RMS over 24 weeks of treatment when using RebiSmart™ for self-injection of Rebif® in a multi-dose cartridge.